NYSE · Pharmaceutical Preparations
ELI LILLY & CoLLY
ELI LILLY & Co (LLY) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations". For fiscal 2025 (ended Dec 31, 2025) it reported revenue of $65.18B, up 44.7% from fiscal 2024. Net income was $20.64B, a net margin of 31.7%. At fiscal year end it had total assets of $112.48B and stockholders' equity of $26.54B (23.6% of assets).
Company profile
- Ticker
- LLY
- Exchange
- NYSE
- Industry (SIC)
- Pharmaceutical PreparationsSIC 2834
- Fiscal year end
- December 31
- Headquarters
- Indianapolis, IN
- Incorporated in
- IN
- SEC filer category
- Large accelerated filer
- SEC CIK
- 59478
Key financials (annual, 10-K)
| Key financials (annual, 10-K) | FY2025ended Dec 31, 2025 | FY2024ended Dec 31, 2024 | FY2023ended Dec 31, 2023 | FY2022ended Dec 31, 2022 | FY2021ended Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Revenue growth (YoY) | +44.70% | +32.00% | +19.56% | +0.79% | — |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| Net income growth (YoY) | +94.90% | +102.08% | -16.08% | +11.88% | — |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
| Total assets | $112.48B | $78.71B | $64.01B | $49.49B | $48.81B |
| Total liabilities | — | — | — | — | — |
| Stockholders' equity | $26.54B | $14.19B | $10.77B | $10.65B | $8.98B |
| Equity ratio (equity / assets) | 23.6% | 18.0% | 16.8% | 21.5% | 18.4% |
| Cash and cash equivalents | $7.27B | $3.27B | $2.82B | $2.07B | $3.82B |
| Shares outstanding | 943.36M | 948.17M | 950.16M | 950.3M | 952.35M |
Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.
Recent SEC filings
All filings on SEC EDGAR- 10-QQuarterly reportPeriod: Sep 30, 2026Filed: Oct 29, 2026
- 8-KCurrent reportFiled: Oct 29, 2026
- 10-QQuarterly reportPeriod: Jun 30, 2026Filed: Aug 5, 2026
- 8-KCurrent reportFiled: Aug 5, 2026
- 8-KCurrent reportFiled: May 20, 2026
- 8-KCurrent reportPeriod: May 4, 2026Filed: May 7, 2026
- 10-QQuarterly reportPeriod: Mar 31, 2026Filed: Apr 30, 2026
- 8-KCurrent reportFiled: Apr 30, 2026
- DEF 14AProxy statementFiled: Mar 20, 2026
- 10-KAnnual reportPeriod: Dec 31, 2025Filed: Feb 12, 2026
Frequently asked questions
What does ELI LILLY & Co do?
The SEC classifies ELI LILLY & Co under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in Indianapolis, IN. It is incorporated in IN. In fiscal 2025 it reported revenue of $65.18B and net income of $20.64B in its annual 10-K report.
What was ELI LILLY & Co's revenue in 2025?
ELI LILLY & Co reported revenue of $65.18B for fiscal 2025, which ended Dec 31, 2025, up 44.7% from $45.04B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 12, 2026.
What was ELI LILLY & Co's net income in 2025?
ELI LILLY & Co reported net income of $20.64B for fiscal 2025, a net margin of 31.7% of revenue.
Where is ELI LILLY & Co listed?
According to the SEC, ELI LILLY & Co's ticker LLY is listed on NYSE.
When does ELI LILLY & Co's fiscal year end?
According to the SEC, ELI LILLY & Co's fiscal year ends on December 31; its latest reported fiscal year (2025) ended Dec 31, 2025.
Companies in the same industry
All US stocksSource: SEC EDGAR · Last updated:
Ver en españolNot investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.